Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1965 1
1970 1
1974 1
1975 2
1976 4
1977 7
1978 7
1979 10
1980 4
1981 2
1982 7
1983 8
1984 7
1985 8
1986 8
1987 8
1988 10
1989 8
1990 12
1991 13
1992 23
1993 20
1994 19
1995 23
1996 13
1997 11
1998 13
1999 14
2000 10
2001 15
2002 16
2003 23
2004 20
2005 18
2006 25
2007 29
2008 43
2009 35
2010 42
2011 50
2012 42
2013 36
2014 49
2015 38
2016 42
2017 38
2018 48
2019 41
2020 8
Text availability
Article attribute
Article type
Publication date

Search Results

853 results
Results by year
Filters applied: . Clear all
Page 1
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
Francis PA, et al. N Engl J Med 2018 - Clinical Trial. PMID 29863451 Free PMC article.
RESULTS: In SOFT, the 8-year disease-free survival rate was 78.9% with tamoxifen alone, 83.2% with tamoxifen plus ovarian suppression, and 85.9% with exemestane plus ovarian suppression (P=0.009 for tamoxifen alone vs. tamoxifen plus ovarian suppression). The 8-year rate of overall survival was 91.5% with tamoxifen alone, 93.3% with tamoxifen plus ovarian suppression, and 92.1% with exemestane plus ovarian suppression (P=0.01 for tamoxifen alone vs. tamoxifen plus ovarian suppression); among the women who remained premenopausal after chemotherapy, the rates were 85.1%, 89.4%, and 87.2%, respectively. ...
RESULTS: In SOFT, the 8-year disease-free survival rate was 78.9% with tamoxifen alone, 83.2% with tamoxifen plus ovarian suppression, and 8 …
Adjuvant ovarian suppression in premenopausal breast cancer
Francis PA, et al. N Engl J Med 2015 - Clinical Trial. PMID 25495490 Free PMC article.
RESULTS: After a median follow-up of 67 months, the estimated disease-free survival rate at 5 years was 86.6% in the tamoxifen-ovarian suppression group and 84.7% in the tamoxifen group (hazard ratio for disease recurrence, second invasive cancer, or death, 0.83; 95% confidence interval [CI], 0.66 to 1.04; P=0.10). ...
RESULTS: After a median follow-up of 67 months, the estimated disease-free survival rate at 5 years was 86.6% in the tamoxifen-ovarian suppr …
Measurement of muscle health in aging
Francis P, et al. Biogerontology 2017 - Review. PMID 28378095 Free PMC article.
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer
Pagani O, et al. N Engl J Med 2014 - Clinical Trial. Among authors: Francis PA. PMID 24881463 Free PMC article.
The rate of freedom from breast cancer at 5 years was 92.8% in the exemestane-ovarian suppression group, as compared with 88.8% in the tamoxifen-ovarian suppression group (hazard ratio for recurrence, 0.66; 95% CI, 0.55 to 0.80; P<0.001). With 194 deaths (4.1% of the patients), overall survival did not differ significantly between the two groups (hazard ratio for death in the exemestane-ovarian suppression group, 1.14; 95% CI, 0.86 to 1.51; P=0.37). ...
The rate of freedom from breast cancer at 5 years was 92.8% in the exemestane-ovarian suppression group, as compared with 88.8% in the tamox …
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
Loi S, et al. J Clin Oncol 2019. Among authors: Francis PA. PMID 30650045 Free PMC article.
The average value of sTILs was 23% (standard deviation, 20%), and 77% of patients had 1% or more sTILs. sTILs were significantly lower with older age ( P = .001), larger tumor size ( P = .01), more nodal involvement ( P = .02), and lower histologic grade ( P = .001). ...In the multivariable model, sTILs added significant independent prognostic information for all end points (likelihood ratio χ(2), 48.9 iDFS; P < .001; χ(2), 55.8 D-DFS; P < .001; χ(2), 48.5 OS; P < .001). ...
The average value of sTILs was 23% (standard deviation, 20%), and 77% of patients had 1% or more sTILs. sTILs were significantly lower with …
853 results
Jump to page
Feedback